about rocks, ergo he should read geology. He had been offered a place at a young age at the University of Oxford, Oxford, England, but the dons thought he should stay down for another year before taking up residence. Because his studies at school had focused on physics, chemistry, and mathematics, yet much of geology is based on palaeontology, his teenage logic led him to an intensive course in biology "to understand fossils." He also spent some time tramping the Welsh hills collecting soil samples for a mining company. Clearly, he was headed for a chair in cardiovascular medicine! Looking back at the chance event that led to medicine, he says, "It was a tortuous path to medicine and a further tortuous path to where I am now. Before university I did a crash course in biology in 2 terms and got an A grade. The inspiring teaching got me interested in biology, though at the time medicine was the last thing in my mind. But I realised that geology was not right and wrote to Oxford telling them about my 'A' in biology, and subsequently I read physiology and psychology in the PPP course-the other P is for philosophy. It was an interesting mix. Fifty percent of the students were arts trained. I was quite comfortable with that. I now believe that being artistic is a key to creativity as a scientist, to think outside the box. The sad thing about a lot of science is that the excitement [of discovery] is not conveyed.
"I discovered that I had an affinity for biology. I enjoy trying to understand its pathways, like physiological mechanisms and their feedbacks, and it is interesting to see that the subject has now developed in this direction. I am not maths inclined-I am more interested in living systems. For a long time the approach in biology was reductionist. Everything was explicable in terms of proteins and subproteins. Now, of course, it is all about maths and large datasets. The belief is that biological systems are explicable mathematically. The contributions from proteomics and genomics have in effect defined the cogs, and now we are working out how the clock works."
While still at Oxford, Professor Haskard took a 1-year course to "convert" to medicine and then, like many other Oxford medical undergraduates, moved to London for his clinical studies. He says, "I went to the Middlesex [Hospital Medical School], now absorbed into UCL [University College London], which was a pretty academic place. I did my house job [for medical registration] alongside Mark Walport, which certainly added an intellectual edge. I then worked in the East End at the London Hospital (now the Royal London Hospital) and rotated through the specialties for 6 months at a time, including rheumatology. It was clear to me even then that it was a specialty that was going to boom. Rheumatoid arthritis was the stock in trade of the department at the London [Hospital], and I just had a feeling that developments in immunology could make a big difference. It was a functional clinical grouping that conveyed to me a tremendous sense of excitement.' With hindsight, Professor Haskard realises that the challenge he was set at the Bone and Joint Research Unit was entirely unsuitable for a 1-year project to be undertaken by a novice. During his fellowship, the Nobel Prize for Physiology or Medicine was awarded to Georges Köhler, César Milstein, and Niels Kaj Jerne for their development of hybridoma techniques. But these were mousebased, and Professor Haskard, in his first project, had been asked to humanise them . . . in a year! The hybridoma research in the Bone and Joint Research Unit did, however, lead to a few articles and importantly trained him to make monoclonal antibodies. When the young Arthritis and Rheumatism Council fellow reviewed progress with his boss, Professor Harry Currey, MD, he seized an opportunity to go abroad and work with "one of the fathers of rheumatology," the late Professor Morris Ziff, MD, PhD, at the University of Texas Southwestern Medical School, Dallas, TX. He had been one of the pioneers of Southwestern Medical School, moving in 1958 from New York City, NY, to Dallas, where he set up a renowned rheumatology department. Then in his 70s and recently retired as chair of rheumatology, Professor Ziff was building up a new, well-funded research team.
Professor Haskard recalls, "When I met Professor Ziff, he said, 'I like what you have been doing, but I don't think it would be suitable to do here.' He showed me a list of the projects he was interested in, including one on lymphocyte trafficking. Basically, he saw rheumatoid synovium as an ectopic lymphoid organ and wanted to understand lymphocyte entry into the tissue. The idea was that if you could prevent lymphocytes from getting into the joints, you could treat arthritis. He had already done a lot of histological work on rheumatoid synovium at the electron microscopic level and had noticed high endothelial venules surrounded by T lymphocyte aggregates similar to those in the paracortex of lymph nodes through which lymphocytes recirculate. In a crude sort of way, we cultured vascular endothelial cells and stimulated them with the cytokines interleukin-1 or interferon γ, which were new at the time, and found that the cells became very sticky for lymphocytes."
The lab's first article on the subject, titled "Human Gamma Interferon Increases the Binding of T lymphocytes to Endothelial Cells" appeared in Clinical and Experimental Immunology in 1985 1 within a year of Professor Haskard's arrival in Dallas. This was a key period in Professor Haskard's career; he had lighted on an area of research that was to boom. He had found an interest in the relatively neglected but crucial subject of intercellular adhesion, and he had started on the path that was to lead to the surprising conclusion that rheumatology and cardiology share a common pathological process, namely, the interaction of immunological entities with the vessel wall.
Soon after returning to London, after 2 years working in the Ziff lab, and now with a clutch of coauthored articles to his name, he wrote an editorial in the Annals of Rheumatic Diseases that set out a stall for the future: "The identification of lymphocyte traffic pathways that involve joints, of lymphocyte subsets that 'home' to synovium, and of the adhesion molecules by which lymphocytes adhere to synovial [endothelial cells] therefore promises exciting opportunities for developing purpose built anti-inflammatory agents that act by blocking lymphocyte migration into the synovium." 2 Professor Haskard says, "The Southwestern campus in Dallas was quite an extraordinary place for me compared to London. It was colossal, with vast spaces and huge labs. While I was there, it also got its first Nobel Prize, which In the late 1980s, the Rheumatology Unit at Guy's Hospital was the perfect setting for a young man fired up by working in the United States and keen to apply immunological ideas to the treatment of rheumatic disease. The work in Dallas led to a thesis on factors regulating lymphocyte traffic in inflammation. Professor Haskard says, "It was a subject that was to be developed enormously by people like Professor Timothy Springer [PhD, at the Center for Blood Research, Harvard Medical School, Boston, MA] and others working on cell adhesion molecules, like the immunoglobulin superfamily cell adhesion molecules, integrins, and selectins. Gabriel Panayi told me that I was not the sort of person for a routine clinical job and that I should stick to research.
"At the time I was one of the few people in the UK with an interest in the molecular basis of leukocyte-endothelial cell interactions and part of a still small field worldwide. Although a fundamental part of biology, it was not a subject that many people had thought much about until the mid-1980s. Therapeutically, the vision was that you might be able to block leukocyte binding to endothelial cells. Industry was gearing up to this in a big way, and there was a lot of support from other academics. I soon obtained a Wellcome Trust senior research fellowship in clinical science.
"Adhesion programmes became something of a bandwagon and antibody treatments have been developed and licensed for multiple sclerosis, psoriasis, and Crohn's disease, athough these have in some ways been too effective because leukoencephalopathies have restricted their application."
Professor Haskard felicitated with a ceremonial shawl at the 2010 Annual Conference of the Indian Society for Atherosclerosis Research, held at the University College of Medical Sciences, Delhi. On the right is Professor Shridhar Dwivedi, dean and professor of medicine and preventive cardiology, Hamdard Institute of Medical Sciences and
Research, New Delhi. Photograph courtesy of Professor Dwivedi.
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With the Wellcome fellowship, Professor Haskard set up a lab where he and colleagues followed a wide variety of projects, almost all with the word "adhesion" somewhere in the title, focusing on the expanding knowledge of cellular adhesion molecules, especially vascular cell adhesion molecule-1. This was a novel adhesion molecule that Professor Haskard had pointed to the existence of functionally during his time in Dallas. As a side product of these studies, the group developed a range of monoclonal antibodies related to various cellular adhesion molecules, which are still widely used. He says, "I was very much hands on in the lab. I loved the bench work-perhaps because my main hobby is gardening, and tissue culture and cell cloning are not dissimilar. In general, this was a productive period that set me up for years."
Investigating the Balance Between the Activation of Proinflammatory and Anti-Inflammatory Genes in the Vascular Endothelium and Macrophages
In 1990, Professor Haskard joined the Royal Postgraduate Medical School on the campus of the Hammersmith Hospital in West London, where he still works (now part of Imperial College), in response to a call from Professor Walport, who was then its head of rheumatology. Here he started to translate what he had learned of cell adhesion in the context of rheumatology into other areas. One particularly fruitful project, which he carried out with nuclear medicine physician Professor Adrien Peters, MD, FMedSci, and others was to image inflammatory activation of vascular endothelium by means of a radiolabelled monoclonal antibody for the cell adhesion molecule E-selectin (also known as the endothelial-leukocyte adhesion molecule-1). Published in the Journal of Nuclear Medicine in 1994, 3 the article was judged manuscript of the year for lab studies.
More recently, Professor Haskard has used a similar concept in imaging inflammation with echocardiography. However, in the mid-1990s, he had hardly entered the cardiology field: it was not until 1996, the year that he joined the British Cardiac Society (now the British Cardiovascular Society), that he started to give 1st-year medical students a course on atherosclerosis.
The importance of Professor Haskard's approach to vascular biology has clearly been well appreciated at Imperial College, leading to several appointments, including head of Vascular Sciences at the National Heart and Lung Institute, deputy director of the British Heart Foundation Centre of Excellence, and head of the Division of Immunology and Inflammation in the Department of Medicine.
Professor Haskard's current cardiovascular research is focused on the balance in the vascular endothelium and macrophages between the activation of proinflammatory genes, which are believed to initiate and sustain atherosclerosis, and anti-inflammatory genes, which are protective. He explains that a key factor being actively investigated in association with bioengineers is the nature of the patterns of flow of blood in the vessels.
In a neat explanation of why atheroma tends to build up at certain sites, it has been shown that, whereas laminar flow switches on protective genes, chaotic flow, at sites such as bifurcations that are susceptible to atherosclerosis, does not. The constant shear associated with laminar flow leads to antioxidant genes being activated, which in turn inhibit the formation of atheroma. This sort of mechanosignalling is widespread and related processes occur in joints, where chondrocytes respond to load.
Among other recent projects in his group, Professor Haskard points to a "seminal discovery" by histopathologist Joseph J. Boyle, MD, PhD, that has therapeutic potential for combatting atheroma. 4 Based on his initial observations from postmortems of coronary deaths, Joe Boyle discovered a transcription factor that responds to heme and stimulates macrophages to adopt a protective programme of gene expression. This enables macrophages that have ingested erythrocytes derived from intraplaque haemorrhage to cope with the toxic iron in haemoglobin and at the same time export lipid from red cell membranes and avoid becoming foam cells. He says, "We now need to find a drug that turns on this transcription factor and thereby activates anti-inflammatory gene expression in macrophages." Professor Haskard is also lead clinician in vascular rheumatology in the Imperial College Healthcare National Health Service Trust, where he takes a special interest in complex cases, especially Behçet's syndrome. First described by the Turkish dermatologist Hulusi Behçet, it is particularly prevalent in parts of the Middle and Far East, which has earned it the name the Silk Road Disease. Professor Haskard says, "I can offer patients an understanding of their disease in terms of underlying inflammatory mechanisms, but as a doctor I try to treat the individual holistically." From time to time, Professor Haskard is approached by headhunters with opportunities to "run something," but he is not interested in "deep admin" and plans to serve out his time at "the Hammersmith," as long-time devotees of the Royal Postgaduate Medical School still call this arm of Imperial College. The fact that he recently retired was, he says, a "mere technicality," and he was immediately reemployed and continues to direct 3 different research groups. His current direction of travel is towards research on posttranscriptional programmes of gene expression and how these are controlled by RNA binding proteins. Professor Haskard enjoys "following his instinct." Reflecting on his career, he says, "The Hammersmith has been good for me, and I have always been at home here. My present boss, Professor Kim Fox, MD (see http:// circ.ahajournals.org/content/119/5/f25), head of the National Heart and Lung Institute, is very supportive of vascular science. We recently moved into the top floor of a brandnew research building opened by [the Rt-Hon] George Osborne [MP, the UK Chancellor of the Exchequer], and this has given us a big lift.
"Looking back, the major contributions I have made have been in better understanding of adhesion molecules and leukocyte-endothelial cell interactions in inflammation, in developing new in vivo techniques with monoclonal antibodies for assessing activation [of inflammatory processes] in the endothelium, in unravelling the roles of complement and natural antibodies in atherosclerosis, and in dissecting the intracellular molecular events that enable complex signalling in endothelial cells and macrophages to control specific programmes of cytoprotective gene expression.
"I set out to be primarily a clinician, but I suppose I have gradually become more of a pure scientist. I am not just driven by the science, but also by mentoring younger people. I love seeing the excitement of their first exposure to original results. I think of myself also as an artist: a scientist tries to quantify things in numbers, whereas an artist deals with experience. I learned from Morris Ziff that there is a value in the style of an oral presentation or in a well-written article that conveys experience as well as information. I enjoy the creative spirit, lateral thinking, and making connections. My projects dictate the techniques rather than the other way round, and I love the creativity of putting it all together. When I am writing an application for a programme grant, I imagine myself painting a picture on a large canvas. I suppose being married to a singer-songwriter and having 3 sons who are all in the arts world helps!"
